MDMA

Category
stimulant
Routes
Oral (PO)
Half-Life (t½)
PO: 8h
Formula
C11H15NO2
Molecular Weight
193.25 g/mol
PubChem CID
1615
Aliases
3,4-Methylenedioxymethamphetamine, Molly, Ecstasy

Pharmacological Mechanism

Reverses SERT, DAT, NET to cause non-exocytotic release of serotonin (principal), dopamine, noradrenaline. Also triggers oxytocin release. Subjective 'entactogenic' state (connection, empathy, emotional openness) distinct from classical psychedelics (5-HT2A agonism minor vs LSD/psilocybin). MAPS Phase 3 trials demonstrated strong PTSD efficacy; FDA rejected 2024 citing trial design concerns (second submission pending).

Half-Life & Elimination Curve (PO: 8h)

100%50%25%12.5%0%0h0×t½8h1×t½16h2×t½24h3×t½32h4×t½40h5×t½0×t½ (0h): 100% remaining (~0.169 mg/L)1×t½ (8h): 50% remaining (~84.3 µg/L)2×t½ (16h): 25% remaining (~42.2 µg/L)3×t½ (24h): 12.5% remaining (~21.1 µg/L)4×t½ (32h): 6.3% remaining (~10.5 µg/L)5×t½ (40h): 3.1% remaining (~5.27 µg/L)
Plasma (PO)t½ Decay (8h)
  • 0×t½0h100% (0.169 mg/L)
  • 1×t½8h50% (84.3 µg/L)
  • 2×t½16h25% (42.2 µg/L)
  • 3×t½24h12.5% (21.1 µg/L)
  • 4×t½32h6.3% (10.5 µg/L)
  • 5×t½40h3.1% (5.27 µg/L)
Elimination t½8h (PO)
Rate Constant (ke)0.0866 h⁻¹
Time to Peak (Tmax)2.29h
Est. Peak (Cmax)0.169 mg/L
Clearance (CL)36.4 L/h
97% Washout (5×t½)40h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References